Assignee: Chugai Seiyaku Kabushiki Kaisha

Location: Tokyo, JP
No. of patents: 512

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

Number	Title	Issue Date
8183005	Pharmaceutical agents for treating HCV infections The present inventors examined the inhibitory activity against HCV replicon of myriocin, fumonisin B1, and ceramide trafficking inhibitor HPA-12, which are compounds derived from microorganisms such as those of the genus Aureobasidium, and found that these co...	05/22/2012
8173824	Process for producing vitamin D derivative using convergent method There are provided a novel process for producing [{(5Z,7E)-(1S,3R,20S)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl}oxy]-N-(2,2,3,3,3-pentafluoropropyl)acetamide, which process is shown in the following reaction scheme: ...	05/08/2012
8173126	Blood VEGF level-lowering agent containing IL-6 antagonist as the active ingredient A blood vascular endothelial growth factor (VEGF) level-lowering agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient. ...	05/08/2012
8158385	Cell death-inducing agent To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. The results suggested that the 2D7 antigen is an HLA class I molecule. Based on this finding, the present inventors examined whether the 2D7 antibody has cell death-inducing acti...	04/17/2012
8143391	Process for producing water-soluble hyaluronic acid modification The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical ...	03/27/2012
8143274	1-(2H)-isoquinolone derivative The present invention provides: a compound represented by the following formula (I): [wherein Y1 and Y4 represent a hydrogen atom or a halogen atom; either one of Y2 and Y3 repres...	03/27/2012
8124733	Tumor suppressor gene A full-length cDNA encoding novel proteins involved in the control of cell proliferation (human Gros1-L and S) was successfully isolated from the human testis cDNA libraries. A full-length cDNA encoding the mouse homologues of the human Gros1 (mouse Gros1-L and S) w...	02/28/2012
8119819	Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of...	02/21/2012
8110662	Antibody directed to protein involved in maintaining differentiation of smooth muscle cells A cDNA fragment participating in the maintenance of smooth muscle differentiation was isolated using a culture system of chicken gizzard smooth muscle cells, the differential display method and the subtracted hybridization method. Using the obtained cDNA sequence as...	02/07/2012
8106002	Anti-cancer agent comprising protein C inhibitor The present invention provides anti-cancer agents comprising protein C inhibitor (PCI) or derivatives thereof as an active ingredient. The anti-cancer agents of the present invention have activities of suppressing cancer cell growth, and cancer metastasis, infiltrat...	01/31/2012
8105799	Methods of screening compounds inhibiting signal transduction through inflammatory cytokines Revealed are that the actions of inflammatory cytokine and the production of inflammatory cytokines such as IL-1 and TNF induced by an inflammatory stimulus as well as the production of other inflammatory cytokines such as IL-6 induced by the former class of inflamm...	01/31/2012
8101719	Humanized anti-CD47 antibody The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host ce...	01/24/2012
8084645	4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors A compound of the present invention, or a pharmaceutically acceptable salt thereof is indicated by formula (1) below: wherein, R1, R2, R3, R4, R5, R6, Q, R	12/27/2011
8080665	Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The...	12/20/2011
8067665	Methods of using human tissue factor-producing knock-in mice A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human ani...	11/29/2011
8067540	Human ALEX1 proteins The present invention provides a novel protein containing an armadillo repeat, a gene encoding this protein, and production and use thereof. The present inventors identified a gene named ALEX1 encoding a human-derived novel armadillo repeat-containing protein. It wa...	11/29/2011
8063046	Benzamide derivative Compounds having high angiogenesis inhibiting activity useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, e.g. cancer and cancer metastasis, are of formula (II), where A	11/22/2011
8062863	Nucleic acids encoding hamster 1GF-1 proteins and methods thereof A polypeptide selected from the group consisting of: (1) a polypeptide having the amino acid sequence of SEQ ID NO: 1, and (2) a polypeptide having an amino acid sequence in which the third amino acid of the amino acid sequence of SEQ ID NO: 1 is substituted by anot...	11/22/2011
8062638	Prevention and treatment of diseases associated with blood coagulation Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently sup...	11/22/2011
8062635	Bispecific antibody substituting for functional proteins The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII/activated bl...	11/22/2011
8058408	Transcription factor having zinc finger domains Using an undifferentiated mouse CL6 cell line, DMSO was added to induce its differentiation into cardiac muscular cells in order to obtain gene fragments whose expression elevated upon the induction. The isolated gene had zinc finger domains and showed a significant...	11/15/2011
8048897	Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatme...	11/01/2011
8048855	Method for suppressing graft-versus-host-disease A method for effectively suppressing GVHD, which occurs after peripheral blood stem cells allotransplantation, without causing marked side effects, and a pharmaceutical composition intended for this purpose and containing human G-CSF as an active ingredient. GVHD ca...	11/01/2011
8039253	Pharmaceutical for prevention and treatment of demyelinating disease A pharmaceutical for prevention and treatment of demyelination-associated neural function impairing diseases contains erythropoietin as an active ingredient, and protectively act on the survival of oligodendrocytes, which form a myelin sheath, in cerebrovascular dem...	10/18/2011
8034903	Degraded TPO agonist antibody The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified an...	10/11/2011
8034345	Anti-PCI antibody for regulating liver regeneration/repair The present invention relates to uses of PCI, which inhibits HGFa activity, and to uses of anti-PCI antibodies, which neutralize HGFa inhibition; and to agents for regulating and controlling tissue regeneration and/or repair, with PCI as an active ingredient; and to...	10/11/2011
8030461	Methods for constructing scDb libraries Bispecific diabody libraries can be constructed from scFv libraries efficiently and without troublesome procedures by a single treatment, placing restriction enzyme sites appropriately for antigen-encoding regions. ...	10/04/2011
8029793	Methods for inhibiting cell proliferation Provided are proliferation inhibitors for cells whose proliferation is stimulated by PTHrP (34-53), comprising a substance inhibiting the binding of PTHrP (1-34) to its receptor. ...	10/04/2011
8025881	BMP antibodies and methods of treating kidney disease using the same When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling p...	09/27/2011
8022247	Process for production of 2,3,4-trifluoro-5-(iodo or bromo)-benzoic acid The invention provides a process for production of 2,3,4-trifluoro-5-(iodo or bromo)benzoic acid, the process comprising a halogenation step in which direct iodination or bromination of 2,3,4-trifluorobenzoic acid is performed with an iodinating agent or brominating...	09/20/2011
8022205	Pyrimidine derivatives as PI3K inhibitor and use thereof A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, represe...	09/20/2011
8022191	PEG-conjugated erythropoietin The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing phy...	09/20/2011
8022047	Combination anticancer agents A cancer therapeutic agent comprising a combination of compound A described below, or a pharmaceutically acceptable salt thereof, and compound B described below, or a pharmaceutically acceptable salt thereof: Compound A represented by the formula of cla...	09/20/2011
8017738	Hemopoietin receptor protein, NR10 The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane typ...	09/13/2011
8017731	Hemopoietic receptor protein, NR10 The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane typ...	09/13/2011
8013208	Methods for producing antibodies This invention provides methods for producing antibodies, wherein the methods comprise the step of administering an immunogen comprising both a target antigen and a background antigen to transgenic animals, into which a gene coding for the background antigen has bee...	09/06/2011
8008437	Cancer-associated genes The present invention is related to a DNA comprising a nucleotide sequence encoding a polypeptide represented by SEQ ID NO:1 or SEQ ID NO:2. The DNA according to the present invention is highly expressed in prostatic adenocarcinoma and ovarian carcinoma, and is a ca...	08/30/2011
8008076	Method of producing a nucleic acid encoding an antibody An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of...	08/30/2011
8008073	Anti-Mpl antibodies Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic ...	08/30/2011
7994318	Coumarin derivatives useful as TNFα inhibitors Novel compounds composition capable of inhibiting TNFα and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these nov...	08/09/2011

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: Chugai Seiyaku Kabushiki Kaisha